Dorsoventral photobiomodulation therapy safely reduces inflammation and sensorimotor deficits in a mouse model of multiple sclerosis
Abstract Background Non-invasive photobiomodulation therapy (PBMT), employing specific infrared light wavelengths to stimulate biological tissues, has recently gained attention for its application to treat neurological disorders. Here, we aimed to uncover the cellular targets of PBMT and assess its...
        Saved in:
      
    
          | Main Authors: | Vincent Escarrat, Davide Reato, Guillaume Blivet, Jacques Touchon, Geneviève Rougon, Rémi Bos, Franck Debarbieux | 
|---|---|
| Format: | Article | 
| Language: | English | 
| Published: | BMC
    
        2024-12-01 | 
| Series: | Journal of Neuroinflammation | 
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12974-024-03294-2 | 
| Tags: | Add Tag 
      No Tags, Be the first to tag this record!
   | 
Similar Items
- 
                
                    Possibilities of pharmacologic correction of cognitive disorders in conditions of experimental equivalent of multiple sclerosis.        
                          
 by: A. A. Nefyodov, et al.
 Published: (2015-06-01)
- 
                
                    Possibilities of pharmacologic correction of cognitive disorders in conditions of experimental equivalent of multiple sclerosis        
                          
 by: Nefyodov A.A., et al.
 Published: (2015-06-01)
- 
                
                    Evaluation of transcriptomic changes after photobiomodulation in spinal cord injury        
                          
 by: Andrew R. Stevens, et al.
 Published: (2025-01-01)
- 
                
                    Effect of photobiomodulation on inflammatory cytokines produced by HaCaT keratinocytes        
                          
 by: Maria Gabriela Rolim Silveira Sá, et al.
 Published: (2024-01-01)
- 
                
                    Transcranial photobiomodulation for reducing symptoms of autism spectrum disorder and modulating brain electrophysiology in children aged 2–7: an open label study        
                          
 by: Yuli Fradkin, et al.
 Published: (2025-01-01)
 
       